메뉴 건너뛰기




Volumn 517, Issue 1, 2013, Pages 60-64

Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib

Author keywords

EGFR; Gefitinib; Lung adenocarcinoma; SNP; Survival

Indexed keywords

GEFITINIB;

EID: 84873523871     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.12.087     Document Type: Article
Times cited : (22)

References (17)
  • 1
    • 10844264628 scopus 로고    scopus 로고
    • An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
    • Amador M.L., et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004, 64:9139-9143.
    • (2004) Cancer Res. , vol.64 , pp. 9139-9143
    • Amador, M.L.1
  • 2
    • 0042413836 scopus 로고    scopus 로고
    • Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group
    • Fossella F., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 2003, 21:3016-3024.
    • (2003) J. Clin. Oncol. , vol.21 , pp. 3016-3024
    • Fossella, F.1
  • 3
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer
    • Fukuoka M., et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003, 21:2237-2246.
    • (2003) J. Clin. Oncol. , vol.21 , pp. 2237-2246
    • Fukuoka, M.1
  • 4
    • 24944503508 scopus 로고    scopus 로고
    • Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer
    • Gandara D., et al. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin. Cancer Res. 2005, 11:5057s-5062s.
    • (2005) Clin. Cancer Res. , vol.11
    • Gandara, D.1
  • 5
    • 19844362355 scopus 로고    scopus 로고
    • Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer
    • Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J. Clin. Oncol. 2005, 23:3235-3242.
    • (2005) J. Clin. Oncol. , vol.23 , pp. 3235-3242
    • Giaccone, G.1
  • 6
    • 39449096577 scopus 로고    scopus 로고
    • Germline polymorphisms in EGFR and survival in patients with lung cancer receiving Gefitinib
    • Gregorc V., et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving Gefitinib. Clin. Pharmacol. Ther. 2008, 83:477-484.
    • (2008) Clin. Pharmacol. Ther. , vol.83 , pp. 477-484
    • Gregorc, V.1
  • 7
    • 33846994719 scopus 로고    scopus 로고
    • The impact of epidermal growth factor receptor gene status on Gefitinib-treated Japanese patients with non-small-cell lung cancer
    • Ichihara S., et al. The impact of epidermal growth factor receptor gene status on Gefitinib-treated Japanese patients with non-small-cell lung cancer. Int. J. Cancer 2007, 120:1239-1247.
    • (2007) Int. J. Cancer , vol.120 , pp. 1239-1247
    • Ichihara, S.1
  • 8
    • 19844375720 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology
    • Janne P.A., Engelman J.A., Johnson B.E. Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 2005, 23:3227-3234.
    • (2005) J. Clin. Oncol. , vol.23 , pp. 3227-3234
    • Janne, P.A.1    Engelman, J.A.2    Johnson, B.E.3
  • 9
    • 33846504706 scopus 로고    scopus 로고
    • A "silent" polymorphism in the MDR1 gene changes substrate specificity
    • Kimchi-Sarfaty C., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
    • (2007) Science , vol.315 , pp. 525-528
    • Kimchi-Sarfaty, C.1
  • 10
    • 40949096067 scopus 로고    scopus 로고
    • Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with Gefitinib
    • Liu G., et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with Gefitinib. Pharmacogenomics J. 2008, 8:129-138.
    • (2008) Pharmacogenomics J. , vol.8 , pp. 129-138
    • Liu, G.1
  • 11
    • 68949208058 scopus 로고    scopus 로고
    • Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib
    • Ma F., et al. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 2009, 66:114-119.
    • (2009) Lung Cancer , vol.66 , pp. 114-119
    • Ma, F.1
  • 12
    • 74549114727 scopus 로고    scopus 로고
    • Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
    • Mitsudomi T., Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010, 277:301-308.
    • (2010) FEBS J. , vol.277 , pp. 301-308
    • Mitsudomi, T.1    Yatabe, Y.2
  • 13
    • 35448992847 scopus 로고    scopus 로고
    • Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer
    • Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., Gottesman M.M. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007, 67:9609-9612.
    • (2007) Cancer Res. , vol.67 , pp. 9609-9612
    • Sauna, Z.E.1    Kimchi-Sarfaty, C.2    Ambudkar, S.V.3    Gottesman, M.M.4
  • 14
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    • Schiller J.H., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
    • (2002) N. Engl. J. Med. , vol.346 , pp. 92-98
    • Schiller, J.H.1
  • 15
    • 58949098405 scopus 로고    scopus 로고
    • Epidermal growth factor receptor intron-1 polymorphism predicts Gefitinib outcome in advanced non-small cell lung cancer
    • Tiseo M., et al. Epidermal growth factor receptor intron-1 polymorphism predicts Gefitinib outcome in advanced non-small cell lung cancer. J. Thorac. Oncol. 2008, 3:1104-1111.
    • (2008) J. Thorac. Oncol. , vol.3 , pp. 1104-1111
    • Tiseo, M.1
  • 16
    • 75749153247 scopus 로고    scopus 로고
    • Predictors of Gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers
    • Tiseo M., et al. Predictors of Gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 2010, 67:355-360.
    • (2010) Lung Cancer , vol.67 , pp. 355-360
    • Tiseo, M.1
  • 17
    • 69549123990 scopus 로고    scopus 로고
    • Functional FEN1 polymorphisms are associated with DNA damage levels and lung cancer risk
    • Yang M., et al. Functional FEN1 polymorphisms are associated with DNA damage levels and lung cancer risk. Hum. Mutat. 2009, 30:1320-1328.
    • (2009) Hum. Mutat. , vol.30 , pp. 1320-1328
    • Yang, M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.